董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles P. Theuer | 男 | Director, President, Chief Executive Officer | 61 | 144.21万美元 | 未持股 | 2020-03-31 |
| Saundra Pelletier | 女 | Director | 50 | 未披露 | 未持股 | 2020-03-31 |
| William R. LaRue | 男 | Director | 68 | 10.53万美元 | 未持股 | 2020-03-31 |
| Martin A. Mattingly | 男 | Director | 63 | 9.40万美元 | 未持股 | 2020-03-31 |
| Paul Walker | 男 | Director | 45 | 10.03万美元 | 未持股 | 2020-03-31 |
| Stephen T. Worland | 男 | Director | 62 | 9.65万美元 | 未持股 | 2020-03-31 |
| J. Rainer Twiford | 男 | Director | 67 | 9.53万美元 | 未持股 | 2020-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles P. Theuer | 男 | Director, President, Chief Executive Officer | 61 | 144.21万美元 | 未持股 | 2020-03-31 |
| Mark C. Wiggins | 男 | Chief Business Officer | 64 | 未披露 | 未持股 | 2020-03-31 |
| Scott B. Brown | 男 | Chief Accounting Officer | 39 | 未披露 | 未持股 | 2020-03-31 |
董事简历
中英对照 | 中文 | 英文- Charles P. Theuer
-
Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018. - Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
- Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.
- Saundra Pelletier
-
Saundra Pelletier于2020年3月加入我们的董事会。Pelletier女士曾担任EvofemBiosciences，Inc.的首席执行官。自2013年2月以来，专注于妇女性健康和生殖健康的临床阶段生物制药公司EVFM（NASDAQ:EVFM）。从2009年到2016年，Pelletier女士担任WomanCare Global International的创始首席执行官，这是一家国际非营利组织，致力于增强妇女和女孩的权能，教育并使其能够对自己的健康做出知情选择。在她的职业生涯早期，佩尔蒂埃曾担任G.D.Searle的企业Vice President和全球特许经营负责人，在那里她管理着一个价值2.5亿美元的专注于女性梦百合的业务部门。在她的众多荣誉中，Pelletier女士被评为《圣地亚哥商业杂志》的2019年年度商业女性。
Saundra Pelletier served as Private Evofem's President and Chief Executive Officer from February 2013 until January 2018 and has served as our President and Chief Executive Officer since January 2018. Ms. Pelletier has been responsible for the company's growth and evolution.She has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women's health care market and what women want. She has also attracted new investor capital, leading multiple equity financing rounds which have raised in excess of $400 million. Throughout her career, she has had oversight and accountability for sales, marketing, operations, medical affairs, regulatory affairs, manufacturing, customer service, business development, and strategic partnerships. Ms. Pelletier was previously the founding CEO of WomanCare Global WCG, an international nonprofit organization focused on creating sustainable supply chains that delivered products to women in more than 100 developing countries. Under her leadership, WCG secured approximately $68M in committed funding from major foundations and organizations and launched an innovative United States educational campaign with American actress/activist Jessica Biel. She served as a member of the board of directors of WCG from November 2017 to February 2020. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit focused on women's health care. She later moved to Women First Health care, where she served as Vice President of Pharmaceuticals and raised $40 million in capital. Ms. Pelletier is a published author, skilled moderator and coveted keynote speaker. Her book, "Saddle Up Your Own White Horse," was published in 2016. She has appeared at the Harvard T. H. Chan School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the International Conference on Climate Change, the MAKERS Conference, Women Deliver, the International Conference on Family Planning, Reproductive Health Supplies Coalition, the University of Virginia's Darden School of Business, the University of Oregon's Lundquist School of Business and the University of California, San Diego. She was awarded the Athena San Diego Pinnacle Award for Life Sciences in 2014 profiled as a "New Champion for Reproductive Health" by the United Nations Foundation in 2015 and named the San Diego Business Journal's 2019 Business Woman of the Year. In 2020 she was named to Inc. Magazine's Female Founders 100 List. In March 2020 she joined the board of directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee. - Saundra Pelletier于2020年3月加入我们的董事会。Pelletier女士曾担任EvofemBiosciences，Inc.的首席执行官。自2013年2月以来，专注于妇女性健康和生殖健康的临床阶段生物制药公司EVFM（NASDAQ:EVFM）。从2009年到2016年，Pelletier女士担任WomanCare Global International的创始首席执行官，这是一家国际非营利组织，致力于增强妇女和女孩的权能，教育并使其能够对自己的健康做出知情选择。在她的职业生涯早期，佩尔蒂埃曾担任G.D.Searle的企业Vice President和全球特许经营负责人，在那里她管理着一个价值2.5亿美元的专注于女性梦百合的业务部门。在她的众多荣誉中，Pelletier女士被评为《圣地亚哥商业杂志》的2019年年度商业女性。
- Saundra Pelletier served as Private Evofem's President and Chief Executive Officer from February 2013 until January 2018 and has served as our President and Chief Executive Officer since January 2018. Ms. Pelletier has been responsible for the company's growth and evolution.She has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women's health care market and what women want. She has also attracted new investor capital, leading multiple equity financing rounds which have raised in excess of $400 million. Throughout her career, she has had oversight and accountability for sales, marketing, operations, medical affairs, regulatory affairs, manufacturing, customer service, business development, and strategic partnerships. Ms. Pelletier was previously the founding CEO of WomanCare Global WCG, an international nonprofit organization focused on creating sustainable supply chains that delivered products to women in more than 100 developing countries. Under her leadership, WCG secured approximately $68M in committed funding from major foundations and organizations and launched an innovative United States educational campaign with American actress/activist Jessica Biel. She served as a member of the board of directors of WCG from November 2017 to February 2020. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit focused on women's health care. She later moved to Women First Health care, where she served as Vice President of Pharmaceuticals and raised $40 million in capital. Ms. Pelletier is a published author, skilled moderator and coveted keynote speaker. Her book, "Saddle Up Your Own White Horse," was published in 2016. She has appeared at the Harvard T. H. Chan School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the International Conference on Climate Change, the MAKERS Conference, Women Deliver, the International Conference on Family Planning, Reproductive Health Supplies Coalition, the University of Virginia's Darden School of Business, the University of Oregon's Lundquist School of Business and the University of California, San Diego. She was awarded the Athena San Diego Pinnacle Award for Life Sciences in 2014 profiled as a "New Champion for Reproductive Health" by the United Nations Foundation in 2015 and named the San Diego Business Journal's 2019 Business Woman of the Year. In 2020 she was named to Inc. Magazine's Female Founders 100 List. In March 2020 she joined the board of directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee.
- William R. LaRue
-
William R. LaRue，2014年7月起，担任本公司董事。2006年6月起，他担任生物制药公司Cadence Pharmaceuticals, Inc.的首席财务官、高级副总裁、财务总管，直到2014年3月它被Mallinckrodt plc收购；2007年4月至2014年3月，担任副秘书。加入Cadence之前，2001-2006，他是生物技术公司Micromet, Inc.（原 CancerVax Corporation）的高级副总裁、首席财务官。2000-2001，他担任eHelp Corporation的执行副总裁、首席财务官，这是一个用户协助软件提供商。此前，1997-2000，他是医疗器械公司Safeskin Corporation的副总裁、财务总管；1993-1997，担任高科技电子系统公司GDE Systems, Inc.的财务总管。2008年10月至今，他担任Neurelis, Inc.的董事，这是一个专业制药公司。他在University of Southern California获得工商管理学士学位、工商管理硕士学位。
William R. LaRue has served as a member of Tracon Pharmaceuticals, Inc. Board since July 2014. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014 and from April 2007 to March 2014 he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. formerly CancerVax Corporation, a biotechnology company, from 2001 to 2006. From 2000 to 2001 Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company from 1993 to 1997. Mr. LaRue currently serves on the board of directors of Conatus Pharmaceuticals, Inc., a position he has held since February 2017. In addition, since December 2017 Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019 and also serves on the board of directors of Alastin Skincare, Inc., a private innovative skincare company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California. - William R. LaRue，2014年7月起，担任本公司董事。2006年6月起，他担任生物制药公司Cadence Pharmaceuticals, Inc.的首席财务官、高级副总裁、财务总管，直到2014年3月它被Mallinckrodt plc收购；2007年4月至2014年3月，担任副秘书。加入Cadence之前，2001-2006，他是生物技术公司Micromet, Inc.（原 CancerVax Corporation）的高级副总裁、首席财务官。2000-2001，他担任eHelp Corporation的执行副总裁、首席财务官，这是一个用户协助软件提供商。此前，1997-2000，他是医疗器械公司Safeskin Corporation的副总裁、财务总管；1993-1997，担任高科技电子系统公司GDE Systems, Inc.的财务总管。2008年10月至今，他担任Neurelis, Inc.的董事，这是一个专业制药公司。他在University of Southern California获得工商管理学士学位、工商管理硕士学位。
- William R. LaRue has served as a member of Tracon Pharmaceuticals, Inc. Board since July 2014. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014 and from April 2007 to March 2014 he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. formerly CancerVax Corporation, a biotechnology company, from 2001 to 2006. From 2000 to 2001 Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company from 1993 to 1997. Mr. LaRue currently serves on the board of directors of Conatus Pharmaceuticals, Inc., a position he has held since February 2017. In addition, since December 2017 Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019 and also serves on the board of directors of Alastin Skincare, Inc., a private innovative skincare company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.
- Martin A. Mattingly
-
Martin A. Mattingly，他是医学博士。他曾担任我们的总裁兼首席执行官（2007年11月14日以来），并于2007年11月14日被任命为董事。他最近任职Ambrx公司，在那里他曾担任其总裁和首席执行官（从2005年9月到2007年）。任职Ambrx公司之前，他曾担任CancerVax公司的执行副总裁兼首席运营官（从2003年5月到2005年9月。从1996年到2003年，他担任Agouron Pharmaceuticals公司和Pfizer公司的多种管理职务，提供高级领导服务。这些职务包括担任Agouron艾滋病部门的总经理、 Pfizer公司的产品开发集团的副总裁，以及Pfizer公司的全球营销计划副总裁。从1983年到1996年，他曾担任Eli Lilly and Company的多种肿瘤学营销和销售管理的职务。
Martin A. Mattingly has served as a member of our Board since December 2014. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until January 2012 following its merger with Synageva BioPharma Corp in November 2011. He also served on the board of directors of Trimeris, Inc. from November 2007 until November 2011. He has been a director of OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, since June 2010 and currently serves on the board of directors of Achieve Life Sciences, Inc. From 2005 to 2007 Dr. Mattingly served as President and Chief Executive Officer of Ambrx, Inc., a biopharmaceutical company. From 2003 to 2005 Dr. Mattingly served as Executive Vice President of CancerVax, Inc., a pharmaceutical company, and as Chief Operating Officer from June 2005 to September 2005. From 1996 to 2003 Dr. Mattingly provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., a pharmaceutical company. From 1983 to 1996 Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company, a biopharmaceutical company. Dr. Mattingly received a Doctor of Pharmacy degree from the University of Kentucky. - Martin A. Mattingly，他是医学博士。他曾担任我们的总裁兼首席执行官（2007年11月14日以来），并于2007年11月14日被任命为董事。他最近任职Ambrx公司，在那里他曾担任其总裁和首席执行官（从2005年9月到2007年）。任职Ambrx公司之前，他曾担任CancerVax公司的执行副总裁兼首席运营官（从2003年5月到2005年9月。从1996年到2003年，他担任Agouron Pharmaceuticals公司和Pfizer公司的多种管理职务，提供高级领导服务。这些职务包括担任Agouron艾滋病部门的总经理、 Pfizer公司的产品开发集团的副总裁，以及Pfizer公司的全球营销计划副总裁。从1983年到1996年，他曾担任Eli Lilly and Company的多种肿瘤学营销和销售管理的职务。
- Martin A. Mattingly has served as a member of our Board since December 2014. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until January 2012 following its merger with Synageva BioPharma Corp in November 2011. He also served on the board of directors of Trimeris, Inc. from November 2007 until November 2011. He has been a director of OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, since June 2010 and currently serves on the board of directors of Achieve Life Sciences, Inc. From 2005 to 2007 Dr. Mattingly served as President and Chief Executive Officer of Ambrx, Inc., a biopharmaceutical company. From 2003 to 2005 Dr. Mattingly served as Executive Vice President of CancerVax, Inc., a pharmaceutical company, and as Chief Operating Officer from June 2005 to September 2005. From 1996 to 2003 Dr. Mattingly provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., a pharmaceutical company. From 1983 to 1996 Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company, a biopharmaceutical company. Dr. Mattingly received a Doctor of Pharmacy degree from the University of Kentucky.
- Paul Walker
-
Paul Walker，自2010年5月在公司董事会任职，自2008年4月，Walker先生担任新企业协会（New Enterprise Associates）的合作伙伴，这是一家投资公司，专注于风险投资和成长型股权投资，他后期主要集中在生物技术和生命科学投资。从2001年1月至2008年3月Walker先生曾在MPM Capital，一家生命科学风险资本公司工作，是MPM BioEquities基金的普通合伙人。从1996年7月至2000年12月Walker先生曾担任富兰克林邓普顿投资（Franklin Templeton Investments）组合经理。 Walker先生从加州大学圣地亚哥分校（the University of California at San Diego）获生物化学和细胞生物学学士学位。Walker先生是特许金融分析师。
Paul Walker has served on our Board since September 2014. Mr. Walker has been a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since April 2008 where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008 Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, PIPE and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000 Mr. Walker served as a portfolio manager at Franklin Resources, Inc., a global investment management organization known as Franklin Templeton Investments. Mr. Walker was a member of the board of directors of TESARO, Inc., an oncology-focused biopharmaceutical company, from May 2010 to May 2014 and is a board observer of Sunesis Pharmaceuticals, Inc., and manages a number of NEA’s other late-stage and public investments. In addition, Mr. Walker is a member of the board of directors of Allakos, Inc., a privately held company focused on the development of drugs to treat eosinophil and mast-cell driven diseases and is a member of the board of directors of Trillium Therapeutics, Inc., a public clinical stage immune-oncology company developing therapies for the treatment of cancer. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the Chartered Financial Analyst designation. - Paul Walker，自2010年5月在公司董事会任职，自2008年4月，Walker先生担任新企业协会（New Enterprise Associates）的合作伙伴，这是一家投资公司，专注于风险投资和成长型股权投资，他后期主要集中在生物技术和生命科学投资。从2001年1月至2008年3月Walker先生曾在MPM Capital，一家生命科学风险资本公司工作，是MPM BioEquities基金的普通合伙人。从1996年7月至2000年12月Walker先生曾担任富兰克林邓普顿投资（Franklin Templeton Investments）组合经理。 Walker先生从加州大学圣地亚哥分校（the University of California at San Diego）获生物化学和细胞生物学学士学位。Walker先生是特许金融分析师。
- Paul Walker has served on our Board since September 2014. Mr. Walker has been a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since April 2008 where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008 Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, PIPE and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000 Mr. Walker served as a portfolio manager at Franklin Resources, Inc., a global investment management organization known as Franklin Templeton Investments. Mr. Walker was a member of the board of directors of TESARO, Inc., an oncology-focused biopharmaceutical company, from May 2010 to May 2014 and is a board observer of Sunesis Pharmaceuticals, Inc., and manages a number of NEA’s other late-stage and public investments. In addition, Mr. Walker is a member of the board of directors of Allakos, Inc., a privately held company focused on the development of drugs to treat eosinophil and mast-cell driven diseases and is a member of the board of directors of Trillium Therapeutics, Inc., a public clinical stage immune-oncology company developing therapies for the treatment of cancer. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the Chartered Financial Analyst designation.
- Stephen T. Worland
-
Stephen T. Worland ，他曾担任董事（2012年6月以来）。他目前是eFFECTOR Therapeutics公司（专注于治疗癌症的新方法的公司）的总裁兼首席执行官和董事。他是Anadys Pharmaceuticals公司（生物制药公司，发现并开发治疗丙型肝炎和癌症）的总裁兼首席执行官和董事（从2007年8月到2011年11月公司被Roche公司收购）。他于2001年加入Anadys公司，并在被任命为首席执行官之前担任过许多行政职务，包括制药总裁和首席科学官。他于1988年在Agouron Pharmaceuticals公司开始他的医疗行业的职业生涯，并通过其HIV蛋白酶抑制剂的成功商业化，以及被Warner-Lambert公司和Pfizer公司的连续收购。他在此期间，担任了多个职位，包括负责抗病毒研究的副总裁和负责分子生物学和生物化学的董事。他是哈佛大学分子生物学美国国立卫生研究院的博士后（从1985年到1988年）。他获得密歇根大学的生物化学最高荣誉学位，以及加州大学的化学博士学位。
Stephen T. Worland,has served as Effector Therapeutics, Inc. President and Chief Executive Officer and as a member of the Old eFFECTOR board of directors since its inception in May 2012, and has served on the Board since August 2021. Previously, Dr. Worland served as Chief Executive Officer and as a member of the board of directors of Anadys Pharmaceuticals, Inc. from August 2007 until its acquisition by Roche Holding AG in 2011. Prior to his appointment as Chief Executive Officer of Anadys Pharmaceuticals, Dr. Worland served as its Chief Scientific Officer and President, Pharmaceuticals. Prior to Anadys Pharmaceuticals, Inc., Dr. Worland was Vice President and Head of Antiviral Research at Pfizer Inc. and Vice President at Warner Lambert Co., where he was responsible for worldwide anti-infectives strategy. Dr. Worland has served as a director of Tracon Pharmaceuticals, Inc. since February 2015 and as a director of Blackstone Medicines since April 2017. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University and completed a Ph.D.in Chemistry at the University of California, Berkeley. He received his B.S. with Highest Honors in Biological Chemistry from the University of Michigan. - Stephen T. Worland ，他曾担任董事（2012年6月以来）。他目前是eFFECTOR Therapeutics公司（专注于治疗癌症的新方法的公司）的总裁兼首席执行官和董事。他是Anadys Pharmaceuticals公司（生物制药公司，发现并开发治疗丙型肝炎和癌症）的总裁兼首席执行官和董事（从2007年8月到2011年11月公司被Roche公司收购）。他于2001年加入Anadys公司，并在被任命为首席执行官之前担任过许多行政职务，包括制药总裁和首席科学官。他于1988年在Agouron Pharmaceuticals公司开始他的医疗行业的职业生涯，并通过其HIV蛋白酶抑制剂的成功商业化，以及被Warner-Lambert公司和Pfizer公司的连续收购。他在此期间，担任了多个职位，包括负责抗病毒研究的副总裁和负责分子生物学和生物化学的董事。他是哈佛大学分子生物学美国国立卫生研究院的博士后（从1985年到1988年）。他获得密歇根大学的生物化学最高荣誉学位，以及加州大学的化学博士学位。
- Stephen T. Worland,has served as Effector Therapeutics, Inc. President and Chief Executive Officer and as a member of the Old eFFECTOR board of directors since its inception in May 2012, and has served on the Board since August 2021. Previously, Dr. Worland served as Chief Executive Officer and as a member of the board of directors of Anadys Pharmaceuticals, Inc. from August 2007 until its acquisition by Roche Holding AG in 2011. Prior to his appointment as Chief Executive Officer of Anadys Pharmaceuticals, Dr. Worland served as its Chief Scientific Officer and President, Pharmaceuticals. Prior to Anadys Pharmaceuticals, Inc., Dr. Worland was Vice President and Head of Antiviral Research at Pfizer Inc. and Vice President at Warner Lambert Co., where he was responsible for worldwide anti-infectives strategy. Dr. Worland has served as a director of Tracon Pharmaceuticals, Inc. since February 2015 and as a director of Blackstone Medicines since April 2017. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University and completed a Ph.D.in Chemistry at the University of California, Berkeley. He received his B.S. with Highest Honors in Biological Chemistry from the University of Michigan.
- J. Rainer Twiford
-
J. Rainer Twiford，2007年6月首次公开募股完成后，他担任我公司董事会成员，目前担任我公司薪酬、提名与治理委员会主席。 1999年起，他担任投资咨询公司Brookline Partners, Inc.的总裁。加入Brookline Partners之前，1987至1991年，他担任Trammell Crow Company的合伙人。他是IPI, Inc和Tracon Pharmaceuticals的董事， 曾担任一家儿童行为健康公司的董事会成员。他在密西西比大学（University of Mississippi）获得学士学位和博士学位，在亚克朗大学（University of Akron）获得硕士学位，在弗吉尼亚大学（University of Virginia）获得法学博士学位。
J. Rainer Twiford has served as a member of our Board since September 2008. Dr. Twiford has been President of Brookline Investments, Inc. formerly Capital Strategies Advisors, Inc., an investment advisory company he founded in 1994 since 1999. Dr. Twiford has been a member of the board of directors of Integrated Photonics, Inc., an optical device company, since November 1999. Prior to founding Brookline Partners, Dr. Twiford was a partner of Trammell Crow Company, a real estate development and investment company, from 1987 to 1991. From June 2007 to July 2013 Dr. Twiford was a member of the board of directors of Care Investment Trust Inc. (now Tiptree Financial Inc.), a real estate investment company. He also served as the Chairman of the Compensation, Nominating and Governance Committee of Care Investment Trust Inc. from September 2011 to July 2013. In addition, Dr. Twiford previously served on the board of a children’s behavioral health company. Dr. Twiford received a B.A. and a Ph.D. from the University of Mississippi, an M.A. from the University of Akron and a J.D. from the University of Virginia. - J. Rainer Twiford，2007年6月首次公开募股完成后，他担任我公司董事会成员，目前担任我公司薪酬、提名与治理委员会主席。 1999年起，他担任投资咨询公司Brookline Partners, Inc.的总裁。加入Brookline Partners之前，1987至1991年，他担任Trammell Crow Company的合伙人。他是IPI, Inc和Tracon Pharmaceuticals的董事， 曾担任一家儿童行为健康公司的董事会成员。他在密西西比大学（University of Mississippi）获得学士学位和博士学位，在亚克朗大学（University of Akron）获得硕士学位，在弗吉尼亚大学（University of Virginia）获得法学博士学位。
- J. Rainer Twiford has served as a member of our Board since September 2008. Dr. Twiford has been President of Brookline Investments, Inc. formerly Capital Strategies Advisors, Inc., an investment advisory company he founded in 1994 since 1999. Dr. Twiford has been a member of the board of directors of Integrated Photonics, Inc., an optical device company, since November 1999. Prior to founding Brookline Partners, Dr. Twiford was a partner of Trammell Crow Company, a real estate development and investment company, from 1987 to 1991. From June 2007 to July 2013 Dr. Twiford was a member of the board of directors of Care Investment Trust Inc. (now Tiptree Financial Inc.), a real estate investment company. He also served as the Chairman of the Compensation, Nominating and Governance Committee of Care Investment Trust Inc. from September 2011 to July 2013. In addition, Dr. Twiford previously served on the board of a children’s behavioral health company. Dr. Twiford received a B.A. and a Ph.D. from the University of Mississippi, an M.A. from the University of Akron and a J.D. from the University of Virginia.
高管简历
中英对照 | 中文 | 英文- Charles P. Theuer
Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.- Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
- Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.
- Mark C. Wiggins
Mark C.Wiggins于2018年5月加入我们，担任我们的首席商务官。在加入我们之前，Wiggins先生曾于2017年至2018年担任Selection Therapeutics，Inc.首席执行官，2012年至2015年担任Elcelyx Therapeutics企业和业务发展高级副总裁，2009年至2011年担任MPEX Pharmaceuticals首席商务官。此前，他曾担任Biogen Idec公司的负责企业和业务发展的执行Vice President（2003年至2009年），以及Idec Pharmaceuticals公司的负责营销和业务发展的Vice President（1998年至2003年）。Wiggins之前还曾担任先灵葆雅（现默克）美国业务开发主管，此外还在辉瑞（Pfizer）和强生公司（McKinsey）任职。Wiggins先生目前任职于Zogenix and Selection的董事会。他在雪城大学（Syracuse University）获得金融学学士学位，在亚利桑那大学（University of Arizona）获得工商管理硕士学位。
Mark C. Wiggins joined us as our Chief Business Officer in May 2018. Prior to joining us, Mr. Wiggins served as Chief Executive Officer at selectION Therapeutics, Inc., from 2017 to 2018 Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics from 2012 to 2015 and Chief Business Officer at Mpex Pharmaceuticals from 2009 to 2011. Prior to this, he served as Executive Vice President of Corporate and Business Development at Biogen Idec, Inc. from 2003 to 2009 and Vice President of Marketing and Business Development at IDEC Pharmaceuticals from 1998 to 2003. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough now Merck, in addition to roles at Pfizer and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He received a B.S. in finance from Syracuse University and an M.B.A. from the University of Arizona.- Mark C.Wiggins于2018年5月加入我们，担任我们的首席商务官。在加入我们之前，Wiggins先生曾于2017年至2018年担任Selection Therapeutics，Inc.首席执行官，2012年至2015年担任Elcelyx Therapeutics企业和业务发展高级副总裁，2009年至2011年担任MPEX Pharmaceuticals首席商务官。此前，他曾担任Biogen Idec公司的负责企业和业务发展的执行Vice President（2003年至2009年），以及Idec Pharmaceuticals公司的负责营销和业务发展的Vice President（1998年至2003年）。Wiggins之前还曾担任先灵葆雅（现默克）美国业务开发主管，此外还在辉瑞（Pfizer）和强生公司（McKinsey）任职。Wiggins先生目前任职于Zogenix and Selection的董事会。他在雪城大学（Syracuse University）获得金融学学士学位，在亚利桑那大学（University of Arizona）获得工商管理硕士学位。
- Mark C. Wiggins joined us as our Chief Business Officer in May 2018. Prior to joining us, Mr. Wiggins served as Chief Executive Officer at selectION Therapeutics, Inc., from 2017 to 2018 Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics from 2012 to 2015 and Chief Business Officer at Mpex Pharmaceuticals from 2009 to 2011. Prior to this, he served as Executive Vice President of Corporate and Business Development at Biogen Idec, Inc. from 2003 to 2009 and Vice President of Marketing and Business Development at IDEC Pharmaceuticals from 1998 to 2003. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough now Merck, in addition to roles at Pfizer and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He received a B.S. in finance from Syracuse University and an M.B.A. from the University of Arizona.
- Scott B. Brown
Scott B.Brown，2015年8月加入本公司，担任财务总监、财务总管。2017年1月，财务总监兼财务总监晋升为Vice President，2019年1月晋升为财务总监，2019年9月晋升为首席会计官。加入我们之前，他曾担任Ardea Biosciences公司（被AstraZeneca公司收购）的财务副董事，在那里他曾领导Ardea Biosciences公司（AstraZeneca公司的子公司）的财务和会计（2013年至2015年）。在此之前，布朗先生于2011年至2013年担任赛生药业公司的财务经理，并于2009年至2011年担任Exelixis，Inc.的财务经理。在Exelixis之前，Brown先生在AcelRx，Inc.，Spinal Elements，Inc.，Stewart Title担任越来越重要的会计职位，并担任毕马威会计师事务所（KPMG，LLP）的审计助理。Brown先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得工商管理硕士学位，在圣地亚哥州立大学（San Diego State University）获得会计学硕士学位，并且是加州注册会计师。
Scott B. Brown joined us as Director, Finance and Controller in August 2015 was promoted to Sr. Director, Finance and Controller in January 2017 was promoted to Vice President, Finance in January 2019 and Chief Accounting Officer in September 2019. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences acquired by AstraZeneca where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.- Scott B.Brown，2015年8月加入本公司，担任财务总监、财务总管。2017年1月，财务总监兼财务总监晋升为Vice President，2019年1月晋升为财务总监，2019年9月晋升为首席会计官。加入我们之前，他曾担任Ardea Biosciences公司（被AstraZeneca公司收购）的财务副董事，在那里他曾领导Ardea Biosciences公司（AstraZeneca公司的子公司）的财务和会计（2013年至2015年）。在此之前，布朗先生于2011年至2013年担任赛生药业公司的财务经理，并于2009年至2011年担任Exelixis，Inc.的财务经理。在Exelixis之前，Brown先生在AcelRx，Inc.，Spinal Elements，Inc.，Stewart Title担任越来越重要的会计职位，并担任毕马威会计师事务所（KPMG，LLP）的审计助理。Brown先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得工商管理硕士学位，在圣地亚哥州立大学（San Diego State University）获得会计学硕士学位，并且是加州注册会计师。
- Scott B. Brown joined us as Director, Finance and Controller in August 2015 was promoted to Sr. Director, Finance and Controller in January 2017 was promoted to Vice President, Finance in January 2019 and Chief Accounting Officer in September 2019. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences acquired by AstraZeneca where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.